A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01058538
Recruitment Status : Completed
First Posted : January 28, 2010
Last Update Posted : February 25, 2014
INC Research
Information provided by (Responsible Party):
Philogen S.p.A.